ABSTRACT
Food allergies (FAs) are of increasing public health concern and are characterized by a large spectrum of diseases. Their diversity is well known for immunologic pathways (IgE, non-IgE-mediated FAs) and natural history. Many other factors and patient characteristics are involved including type of food, exposure route, allergic comorbidities, gender, racial and ethnic backgrounds, cofactors and health conditions. Food allergen components and sensitization profiles are also involved in FA phenotypes. A new approach to chronic disorders based on the identification of phenotypes through extensive knowledge of all the complex components is also applicable to FAs and could lead towards integrative care management. Diagnostic biomarkers for FAs are emerging which also contribute to better care modalities. The aim of this article was to highlight current knowledge regarding the phenotypic diversity of FA. This review will focus on IgE-mediated FAs and how identifying phenotypes may help to better understand the pathophysiological complexity, improve diagnosis and lead to personalized treatment strategies.
Subject(s)
Allergens/immunology , Food Hypersensitivity/diagnosis , Food Hypersensitivity/immunology , Food/adverse effects , Phenotype , Age Factors , Animals , Biomarkers , Comorbidity , Disease Susceptibility , Ethnicity , Food Hypersensitivity/epidemiology , Food Hypersensitivity/therapy , Humans , Hypersensitivity, Immediate/diagnosis , Hypersensitivity, Immediate/immunology , Immunization , Immunoglobulin E/immunology , Precision Medicine/methods , Prognosis , Risk Factors , Severity of Illness Index , Sex FactorsABSTRACT
Inhaled corticosteroids (ICSs) are the cornerstone and the first stage of asthma treatment. The objective of this study was to synthesize data on the potential effects of ICSs on growth in children. Studies on the short-term impact of ICSs on growth evaluated by knemometry cannot be extrapolated to the medium or long term and therefore have no utility in real life for a given person. In the medium term, the various ICSs given at the usual doses cause a small reduction in growth after 6 months of treatment. This slowdown occurs at the beginning of treatment, especially in younger children, and the growth velocity corrects itself later but without catching up. In the long term, the prolonged use of ICSs seems to induce a small reduction in the final size in adulthood (close to 1cm) occurring in the first 2 years of treatment without worsening over time. The impact of gender, age at onset of treatment, different ICSs, modes of inhalation, and severity of asthma should also be studied further. The benefit of ICSs in asthma treatment is greater than the risk of side effects, including on growth. The majority of the therapeutic effect is obtained for small to moderate doses of ICSs. Regular adjustment of ICS dose for optimal asthma control should also reduce ICS dose and the impact on growth.
Subject(s)
Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/adverse effects , Asthma/drug therapy , Growth/drug effects , Administration, Inhalation , Child , HumansABSTRACT
Juvenile dermatomyositis is the leading cause of chronic idiopathic inflammatory myopathy of auto-immune origin in children. Lung involvement in inflammatory myopathies is well described in adults, involving mostly interstitial lung disease, aspiration pneumonia and alveolar hypoventilation. We propose to describe its specificities in children. Pulmonary involvement may be asymptomatic and therefore must be systematically screened for. In case of clinical or functional respiratory abnormality, a chest computed tomographic (CT) scan is necessary. In children, a decrease of respiratory muscle strength seems common and should be systematically and specifically searched for by non-invasive and reproducible tests (sniff test). Interstitial lung disease usually associates restrictive functional defect, impairment of carbon monoxide diffusion and interstitial lung disease on CT scan. As in adults, the first-line treatment of juvenile dermatomyositis is based on corticosteroids. Corticosteroid resistant forms require corticosteroid bolus or adjuvant immunosuppressive drugs (methotrexate or cyclosporine). There is no consensus in pediatrics for the treatment of diffuse interstitial lung disease. Complications of treatment, including prolonged steroid therapy, are frequent and therefore a careful assessment of the treatments risk-benefit ratio is necessary, especially in growing children.
Subject(s)
Dermatomyositis/complications , Lung Diseases/etiology , Adult , Child , Dermatomyositis/drug therapy , Disease Progression , Humans , Immunosuppressive Agents/therapeutic use , Lung Diseases/diagnosis , Lung Diseases/drug therapy , Respiratory Function TestsSubject(s)
Lemierre Syndrome/diagnostic imaging , Tomography, X-Ray Computed , Tonsillitis/diagnostic imaging , Anti-Bacterial Agents/therapeutic use , Child , Diagnosis, Differential , Disease Progression , Humans , Josamycin/therapeutic use , Male , Radiographic Image Enhancement , Tonsillitis/drug therapySubject(s)
Enteral Nutrition , Gastroscopy , Gastrostomy/methods , Home Care Services , Adolescent , Child , Child, Preschool , Female , Humans , Infant , MaleSubject(s)
Diet , Food Hypersensitivity , Quality of Life , Adolescent , Child , Child, Preschool , Humans , Infant , Recurrence , Surveys and QuestionnairesABSTRACT
Tuberculous otitis media is a rare disease. Its diagnosis is often made late. We report the case of a 13-year-old girl presenting with a right chronic otitis media and a massive and painful cervical adenitis. High resolution CT-scan revealed cervical and mediastinal adenitis associated with extensive lesions involving the middle ear, mastoid air cells, and sphenoidal bone. The diagnosis of tuberculous otitis media was made on a positive tuberculin skin test and on the identification of Mycobacterium tuberculosis in gastric juices. The young girl progressed well after 9 months of antituberculous chemotherapy.
